<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30193219</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1768-3254</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>157</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>European journal of medicinal chemistry</Title>                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Discovery of new 2, 5-disubstituted 1,3-selenazoles as selective human carbonic anhydrase IX inhibitors with potent anti-tumor activity.</ArticleTitle>            <Pagination>                <MedlinePgn>1214-1222</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(18)30768-2</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2018.08.096</ELocationID>            <Abstract>                <AbstractText>A series of disubstituted selenazole derivatives was synthetized and evaluated as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors against the human (h) isoforms hCA I, II, IV, VA, VB and IX, involved in a variety of diseases including glaucoma, retinitis pigmentosa, epilepsy, arthritis and tumors. The investigated compounds showed potent inhibition against the tumor-associated transmembrane hCA IX, with K<sub>I</sub>s in the subnanomolar - low nanomolar range, and were evaluated for their effects on cell viability against the human prostate (PC3) and breast (MDA-MB-231) cancer cell lines, showing effective anti-tumor activity. These selenazoles are interesting leads for the development of new, isoform-selective CA IX inhibitors.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Angeli</LastName>                    <ForeName>Andrea</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of University of Florence, NEUROFARBA Dept, Sezione di Scienze Farmaceutiche, Via Ugo Schiff 6, Sesto Fiorentino, 50019, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Trallori</LastName>                    <ForeName>Elena</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>NEUROFARBA Department, Section of Pharmacology and Toxicology, Università Degli Studi di Firenze, Viale Pieraccini 6, 50139, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferraroni</LastName>                    <ForeName>Marta</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of University of Florence, Department of Chemistry &quot;Ugo Schiff&quot;, Via Della Lastruccia 13, Sesto Fiorentino, I-50019, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Di Cesare Mannelli</LastName>                    <ForeName>Lorenzo</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>NEUROFARBA Department, Section of Pharmacology and Toxicology, Università Degli Studi di Firenze, Viale Pieraccini 6, 50139, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ghelardini</LastName>                    <ForeName>Carla</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>NEUROFARBA Department, Section of Pharmacology and Toxicology, Università Degli Studi di Firenze, Viale Pieraccini 6, 50139, Florence, Italy.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Supuran</LastName>                    <ForeName>Claudiu T</ForeName>                    <Initials>CT</Initials>                    <AffiliationInfo>                        <Affiliation>Department of University of Florence, NEUROFARBA Dept, Sezione di Scienze Farmaceutiche, Via Ugo Schiff 6, Sesto Fiorentino, 50019, Florence, Italy. Electronic address: claudiu.supuran@unifi.it.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Eur J Med Chem</MedlineTA>            <NlmUniqueID>0420510</NlmUniqueID>            <ISSNLinking>0223-5234</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 4.2.1.1</RegistryNumber>                <NameOfSubstance UI="D000071231">Carbonic Anhydrase IX</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000071231" MajorTopicYN="N">Carbonic Anhydrase IX</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002257" MajorTopicYN="N">Carbonic Anhydrase Inhibitors</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055808" MajorTopicYN="Y">Drug Discovery</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Carbonic anhydrase</Keyword>            <Keyword MajorTopicYN="N">Inhibitor</Keyword>            <Keyword MajorTopicYN="N">Metalloenzymes</Keyword>            <Keyword MajorTopicYN="N">Selenazole</Keyword>            <Keyword MajorTopicYN="N">Selenium</Keyword>            <Keyword MajorTopicYN="N">Tumors</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>31</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30193219</ArticleId>            <ArticleId IdType="pii">S0223-5234(18)30768-2</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejmech.2018.08.096</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>